The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Unmet needs that remain in stage 3B and R/R amyloidosis
In this video, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, gives an overview of unmet needs in patients with stage 3B and relapsed/refractory (R/R) amyloidosis. In those with stage 3B disease, Prof. Kastritis highlights the challenge of reducing early mortality and improving supportive care. Patients with R/R disease who have been exposed to daratumumab remain a challenge to treat, although novel agents are being explored for this population. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
